APP Pharmaceuticals Issues A Nationwide Voluntary Recall Of Irinotecan Hydrochloride Injection
Sun, 27 Mar 2011 15:33:00 -0500
APP Pharmaceuticals, Inc., (APP) announced today that it has issued a voluntary recall of five lots of Irinotecan Hydrochloride Injection, which is used for recurrent or progressive metastatic colorectal cancer. This recall is being conducted as a precautionary measure and there have been no reports to dates of adverse events related to the recalled products.
Manage your FDA Subscriptions:
- Update your preferences or unsubscribe
- Questions about this service? support@govdelivery.com
- Other inquiries? webmail@oc.fda.gov
U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420
No comments:
Post a Comment